Biogen's anti-tau Alzheimer's drug misses Phase 2 goal, but claims signs of efficacy

May 14, 2026 07:32 AM EDT R&D Bio­gen's an­ti-tau Alzheimer's drug miss­es Phase 2 goal, but claims signs of ef­fi­ca­cy Max Gelman Senior Editor Here we go again? Bio­gen re­port­ed heav­i­ly an­tic­i­pat­ed Alzheimer’s da­ta on Thurs­day morn­ing, say­ing its tau-tar­get­ing drug BI­IB080 did not meet its pri­ma­ry end­point in … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER